COLI
|
Intactness
|
Colorectal cancer
|
Changes dynamically at stages I to IV, peaking at stage II
|
[249]
|
Intactness
|
Prostate cancer
|
Metastasis
|
[250]
|
COL1A1
|
Breast cancer
|
Development and progression along with COL3A1 and COL4A1
|
[251]
|
COL1A2
|
Colorectal cancer
|
Proliferation, migration, and invasion
|
[252]
|
COL1A2
|
Hepatocellular cancer
|
Metastasis
|
[253]
|
N-terminal telopeptide
|
NSCLC
|
Overall survival
|
[254]
|
N-terminal telopeptide
|
Head and neck SCC
|
Overall survival along with N-terminal telopeptide of COLIII
|
[255]
|
Pyridinoline crosslinked C-terminal telopeptide (serum)
|
Breast cancer
|
Recurrence
|
[256]
|
N-terminal telopeptide (urine)
|
Breast cancer with bone metastases
|
Survival prognosis with zoledronic acid treatment for 3 months
|
[257]
|
COLII
|
COL2A1
|
High-grade serous ovarian cancer
|
Recurrence
|
[258]
|
COL2A1
|
Chondrosarcoma
|
Frequent mutations
|
[259]
|
COLIII
|
COL3A1
|
Breast cancer
|
Irregular margin status and mitotic activity
|
[260]
|
COLIV
|
Intactness
|
Advanced gastric carcinoma
|
The depth of wall penetration and stage
|
[261]
|
Intactness
|
Oral SCC
|
Positive lymph node status
|
[262]
|
Intactness
|
Colorectal cancer
|
Liver metastases
|
[263]
|
7S domain (serum)
|
Hepatocellular carcinoma
|
Intractable ascites
|
[264]
|
COL4A1
|
PDAC
|
Aggressive progression
|
[265]
|
COL4A1 (urine)
|
Bladder cancer
|
Recurrence
|
[266]
|
COL4A3
|
Gastric carcinomas
|
Cancer size, lymphatic invasion, venous invasion, TNM stage, and histologically distinction
|
[267]
|
COLV
|
Intactness
|
Resected NSCLC
|
Overall survival
|
[268].
|
COLVI
|
COL6A1
|
Cervical cancer
|
Overall and recurrent-free survival
|
[269]
|
COLXI
|
COL11A1
|
Esophageal SCC
|
Advanced clinical stage and lymph node metastases
|
[270]
|
COLXIII
|
COL13A1 (urine)
|
Bladder cancer
|
Recurrence
|
[266]
|
COLXVII
|
Intactness
|
Colorectal cancer
|
Invasion and metastasis
|
[271]
|
Intactness
|
SCC
|
Invasion
|
[272]
|
Intactness
|
Colon cancer
|
Metastasis
|
[273]
|
COLXXIII
|
Intactness (tissue and urine)
|
NSCLC
|
Recurrence
|
[274]
|